New hope for cirrhosis in hep C patients
An experimental interferon-free multidrug therapy was well-tolerated and cured hepatitis C infection in more than 90% of patients with liver cirrhosis.
The phase III clinical trial investigated outcomes of a combination of antiretroviral agents and ribavirin in patients with hepatitis C and cirrhosis, who are typically unable to tolerate existing interferon therapies because of their severe toxic effects.
Among patients with cirrhosis, interferon therapy is associated with an increased risk of severe complications, including death, the study authors reported.
But the new regimen is interferon free and consists of multiple agents – ABT-450 with ritonavir, ombitasvir, dasabuvir and ribavirin. Investigators randomised 380 patients to receive either 12 or 24 weeks of the therapy.
At the 12-week post-treatment follow-up, 91.8% of patients who took the treatments for 12 weeks had no trace of hepatitis C detected in their